Fintel reports that on October 14, 2025, Canaccord Genuity maintained coverage of Regeneron Pharmaceuticals (NasdaqGS:REGN) ...

Regeneron is expected to announce its fiscal third-quarter earnings later this month, and analysts project a double-digit ...

Johnson & Johnson's Q3 2025 earnings beat forecasts, with strong oncology sales and raised guidance. Click for my updated ...

EyePoint Pharmaceuticals outlines Phase 3 trials for Duravyu in diabetic macular edema, backed by $150 million in new funding ...

Regeneron Pharmaceuticals recently received a financial thumbs-up from Citigroup, with a new price target of $660.00 ...

Regeneron Pharmaceuticals received a reaffirmed "buy" rating from Canaccord Genuity Group, signaling strong investor ...

The Dow Jones Index jumped 400 points Monday on Trump's tariff comments. Bloom Energy soared on deal news Monday.

Detailed price information for Regeneron Pharmaceuticals (REGN-Q) from The Globe and Mail including charting and trades.

Achieve Life Sciences (ACHV) and Disc Medicine (IRON) stocks rally after getting selected among winners of initial FDA ...

Detailed price information for Regeneron Pharmaceuticals (REGN-Q) from The Globe and Mail including charting and trades.

The FDA launched a new voucher program to fast-track reviews, naming nine experimental drugs for cancer, diabetes, addiction, ...